The glucagon receptor component adds metabolic effects beyond appetite suppression, including enhanced fat oxidation and energy expenditure
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications with specific UK licences: some are approved for type 2 diabetes management (semaglutide [Ozempic], dulaglutide [Trulicity], liraglutide [Victoza]), while others are specifically licensed for weight management in adults with obesity or overweight with weight-related comorbidities (semaglutide [Wegovy], liraglutide [Saxenda])
Simply request a consultation, and our board-certified physicians will review your medical history, tailor a treatment plan, and prescribe the most effective GLP-1 medication for you
GLP-1 then sends a signal to your pancreas that causes the release of insulin, which tells your cells to take in glucose from your blood, lowering your blood sugar
More than 20 million doses of GLP-1 medication were used worldwide in 2023 (Vinfuture)